Koyfin Home > Directory > Health Care > Biogen Inc > Repurchase of Common Stock

Biogen Inc Repurchase of Common Stock Chart (BIIB)

Biogen Inc annual/quarterly Repurchase of Common Stock from 2010 to 2020.
  • Biogen Inc Repurchase of Common Stock for the quarter ending September 09, 2020 was $-1,250m a -67.45% increase of 843m year over year
  • Biogen Inc Repurchase of Common Stock for the last 12 months ending September 09, 2020 was $-8,372m a 29.91% decrease of -2,504m year over year
  • Biogen Inc Annual Repurchase of Common Stock for 2019 was $-5,868m a 25.83% decrease of -1,516m from 2018
  • Biogen Inc Annual Repurchase of Common Stock for 2018 was $-4,353m a 68.63% decrease of -2,987m from 2017
  • Biogen Inc Annual Repurchase of Common Stock for 2017 was $-1,365m a 26.76% decrease of -365m from 2016
Other Cash Flow Metrics:
  • Biogen Inc Cash Flow from Operations for the quarter ending September 09, 2018 was $1,736m a 12.54% increase of 218m year over year
  • Biogen Inc Levered Free Cash Flow (FCF) for the quarter ending September 09, 2018 was $1,098m a 0.14% increase of 2m year over year
  • Biogen Inc Total Revenue for the quarter ending December 12, 2018 was $3,526m a 11.21% increase of 395m year over year
View Chart On Koyfin

Quarterly BIIB Repurchase of Common Stock Data

09/2020$-1,250m
06/2020$-2,809m
03/2020$-2,220m
12/2019$-2,093m
09/2019$-718m
06/2019$-2,402m
03/2019$-656m
12/2018$-1,353m
09/2018$0m
06/2018$-2,750m

Annual BIIB Repurchase of Common Stock Data

2019$-5,868m
2018$-4,353m
2017$-1,365m
2016$-1,000m
2015$-5,000m
2014$-887m
2013$-400m
2012$-985m
2011$-498m
2010$-2,078m